 |
|
Imipramine Dose-Response Relationship in Panic Disorder With AgoraphobiaPreliminary Findings
Matig R. Mavissakalian, MD;
James M. Perel, PhD
Arch Gen Psychiatry. 1989;46(2):127-131.
Abstract
• At the end of a two-week single-blind placebo baseline, 43 patients with a diagnosis of panic disorder with agoraphobia without significant dysphoria-depression and with moderate to severe panic and phobic symptoms were assigned to, and 32 of them completed, a placebo-controlled (n = 7) doseresponse study with three weight-adjusted imipramine hydrochloride dosages: 0.5 mg/kg/d (n =10), 1.5 mg/kg/d (n = 9), and 3 mg/kg/d (n = 6). Eleven patients, three from the medium-dose and eight from the high-dose conditions, dropped out owing to side effects. No instructions or encouragement for selfdirected exposure to phobic situations or other coping strategies with panic or fear were given throughout the trial. Compliance, as assessed by pill counts and by plasma tricyclic levels, was high. Results provided strong evidence for a positive dose-response relationship on panic and phobic symptoms and confirmed earlier suggestions (1) that imipramine without concurrent exposure possesses a significant antipanic and antiphobic effect, (2) that improvement correlates primarily with imipramine but not N-desmethylimipramine plasma levels, and (3) that side effects prevent optimum dose buildup in a substantial proportion of patients with this disorder.
Author Affiliations
From the Department of Psychiatry, College of Medicine, Ohio State University, Columbus (Dr Mavissakalian); and the Clinical Pharmacology Program, School of Medicine, University of Pittsburgh (Dr Perel).
Footnotes
Accepted for publication April 22, 1988.
Reprint requests to Department of Psychiatry, Ohio State University, 473 W 12th Ave, Columbus, OH 43210 (Dr Mavissakalian).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants
Anderson and Tomenson
J Psychopharmacol 1994;8:238-249.
ABSTRACT
A Comparison of Fluvoxamine, Cognitive Therapy, and Placebo in the Treatment of Panic Disorder
Black et al.
Arch Gen Psychiatry 1993;50:44-50.
ABSTRACT
Maintenance Drug Treatment of Panic Disorder: I. Results of a Prospective, Placebo-Controlled Comparison of Alprazolam and Imipramine
Schweizer et al.
Arch Gen Psychiatry 1993;50:51-60.
ABSTRACT
Imipramine in panic disorder. 1. Clinical response and pharmacological changes
Nutt and Glue
J Psychopharmacol 1991;5:56-64.
ABSTRACT
|
